Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.

In cell and mouse models, miR181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.

Researchers can use this model to identify pre-clinical systems or potential treatments for multiple cancer types.

In mouse models with a deadly form of pediatric brain cancer, an immune stimulatory gene therapy increased median survival.

Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.